BiotechTube

Adjuvant Immunomodulatory (IM) Therapy

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis IIIA

Conditions

Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A

Trial Timeline

Sep 28, 2020 → Aug 1, 2027

NCT ID
NCT04360265

About Adjuvant Immunomodulatory (IM) Therapy

Adjuvant Immunomodulatory (IM) Therapy is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Mucopolysaccharidosis IIIA. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04360265. Target conditions include Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome.

What happened to similar drugs?

5 of 14 similar drugs in Mucopolysaccharidosis IIIA were approved

Approved (5) Terminated (1) Active (9)
✅laronidaseSanofiApproved
✅LaronidaseSanofiApproved
✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
🔄Aldurazyme + Aldurazyme + placeboSanofiPhase 3
✅LaronidaseSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04360265Phase 3Recruiting

Competing Products

20 competing products in Mucopolysaccharidosis IIIA

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
29
anakinraSwedish Orphan BiovitrumPhase 1/2
32
laronidaseSanofiApproved
43
LaronidaseSanofiApproved
43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
40
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
40
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
40
LaronidaseSanofiApproved
35
JR-141JCR PharmaceuticalsPhase 2/3
38
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
36
JR-446JCR PharmaceuticalsPhase 1/2
39
JR-171JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2
39
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
44
JR-141JCR PharmaceuticalsPhase 3
47
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 1/2
32